Amorfix appoints Mr. Johannes Roth to Board of Directors

TSX: AMF

TORONTO, Dec. 5, 2013 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that it has appointed Johannes Minho Roth, Chairman of the Board of FiveT Capital Holding AG, to its Board of Directors.

Mr. Roth is the founding director and partner at FiveT Capital Holding AG, a Pfäffikon/Switzerland-based innovative financial holdings firm with activities in quantitative tailored investment and risk management solutions for institutional investors and high net-worth individuals with sophisticated wealth management, investment and risk requirements. He has many years of experience as a CIO and portfolio manager for FiveT Capital AG and as an equity specialist and proprietary trader at Baaderbank AG. 

Mr. Roth holds a masters degree (diploma) in economics from Hohenheim University and is a board member of Insilico Biotechnology AG, a Stuttgart/Germany-based global leader in providing solutions and software for the simulation of living cells.

"We are extremely pleased to welcome Mr. Roth to the Amorfix Board", said Dr. Robert Gundel, President and CEO of Amorfix.  Mr. Roth's experience in business and finance on a global scale along with his other impressive qualifications will be a great addition to our Board and instrumental for our plans to take the Company to the next level".

About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this technology, Amorfix is developing novel antibody therapeutics and companion diagnostics for cancer and amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample: Epitope Protection™ and AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these technologies has generated a cerebrospinal fluid (CSF) screening test for both Alzheimer's disease (AD) and mild cognitive impairment (MCI), and an ultrasensitive method for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood from animal models of AD. For more information about Amorfix, visit www.amorfix.com.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



 

SOURCE Amorfix Life Sciences Ltd.

For further information:

Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
bob.gundel@amorfix.com

Warren Whitehead
Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 644-7358
Fax: (416) 847-6899
warren.whitehead@amorfix.com